Table 3 Costs, outcomes and ICERs compared to DTG + ABC/3TC
From: Improving access to antiretrovirals in China: economic analyses of dolutegravir in HIV-1 patients
Treatment naïve | First line failures | |||
|---|---|---|---|---|
DTG + TDF/3TC | EFV + TDF/3TC | DTG + TDF/3TC | LPV/r + TDF/3TC | |
Efficacy | ||||
Responders (%) | 75.3 | 64.0 | 74.8 | 58.4 |
Months of response | 41.7 | 36.7 | 41.4 | 33.7 |
Life years | 4.728 | 4.728 | 4.728 | 4.728 |
QALYs | 4.232 | 4.227 | 4.224 | 4.221 |
Costs (in RMB) | ||||
Total | 219,259 | 221,605 | 238,746 | 244,364 |
ART | 24,744 | 11,958 | 24,744 | 24,744 |
Routine care | 173,930 | 184,364 | 187,859 | 192,237 |
AEs and other events | 13,297 | 13,357 | 13,092 | 13,182 |
Indirect costs | 7289 | 11,926 | 13,052 | 14,202 |
ICERs (including indirect costs) | ||||
Costs/responder | DTG dominates | DTG dominates | ||
Costs/QALY | DTG dominates | DTG dominates | ||
ICERs (excluding indirect costs) | ||||
Costs/responder | DTG dominates | DTG dominates | ||
Costs/QALY | DTG dominates | DTG dominates | ||